Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Sara Alsterlind HurvitzCristina SauraMafalda OliveiraMaureen E TrudeauBeverly MoySuzette DelalogeWilliam GradisharSung-Bae KimBarbara HaleyLarisa RyvoMing-Shen DaiVladimir MilovanovJesús AlarcónSujith KalmadiEduardo CronembergerCristiano SouzaLuciana LandeiroRon BoseJudith BebchukFairooz KabbinavarRichard BryceKiana KeyvanjahAdam M BrufskyPublished in: The oncologist (2021)
In a subgroup of patients with central nervous system (CNS) metastases from HER2-positive breast cancer after two or more previous HER2-directed regimens, the combination of neratinib plus capecitabine was associated with improved progression-free survival and CNS outcomes compared with lapatinib plus capecitabine. These findings build on previous phase II and III studies describing efficacy of neratinib in the prevention and treatment of CNS metastases, and support a role for neratinib as a systemic treatment option in the management of patients with HER2-positive brain metastases following antibody-based HER2-directed therapies.
Keyphrases
- positive breast cancer
- phase iii
- phase ii
- clinical trial
- open label
- free survival
- brain metastases
- blood brain barrier
- metastatic breast cancer
- phase ii study
- small cell lung cancer
- locally advanced
- cerebrospinal fluid
- metastatic colorectal cancer
- study protocol
- metabolic syndrome
- adipose tissue
- combination therapy
- radiation therapy
- replacement therapy